XK
APLS

Xact Kapitalforvaltning’s Apellis Pharmaceuticals APLS Stock Holding History

Xact Kapitalforvaltning’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		$343K Hold
12,800
– – 0.01% 927
2019
Q4 		$392K Buy
+12,800
New +$354K 0.01% 1116

Other funds holding APLS

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Xact Kapitalforvaltning's APLS Position: Q1 2020 in Review

Xact Kapitalforvaltning held its Apellis Pharmaceuticals (APLS) position steady in Q1 2020 at 12,800 shares worth $343K. The position accounts for 0.01% of the portfolio, ranked #927.

Xact Kapitalforvaltning first reported a position in APLS in Q4 2019 and has held it in 2 quarters since. The position peaked at $392K in Q4 2019. 143 funds tracked by Wall St. Rank hold APLS as of Q1 2020.

  • Xact Kapitalforvaltning held 12,800 shares of Apellis Pharmaceuticals worth $343K as of Q1 2020.
  • Xact Kapitalforvaltning left its Apellis Pharmaceuticals share count unchanged in Q1 2020.
  • Apellis Pharmaceuticals made up 0.01% of Xact Kapitalforvaltning's portfolio in Q1 2020, its #927 holding.
  • Xact Kapitalforvaltning first reported a position in Apellis Pharmaceuticals in Q4 2019 and has held it in 2 quarters since.
  • Xact Kapitalforvaltning's Apellis Pharmaceuticals position peaked at $392K in Q4 2019.
  • 143 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q1 2020.

Based on Xact Kapitalforvaltning's 13F filing for Q1 2020, filed 14 May 2020.